𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development

✍ Scribed by Daryl C. Drummond; Charles O. Noble; Mark E. Hayes; John W. Park; Dmitri B. Kirpotin


Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
753 KB
Volume
97
Category
Article
ISSN
0022-3549

No coin nor oath required. For personal study only.

✦ Synopsis


Liposomes represent a widely varied and malleable class of drug carriers generally characterized by the presence of one or more amphiphile bilayers enclosing an interior aqueous space. Thus, the pharmacological profile of a particular liposomal drug formulation is a function not only of the properties of the encapsulated drug, but to a significant extent of the pharmacokinetics, biodistribution, and drug release rates of the individual carrier. Various physicochemical properties of the liposomal carriers, the drug encapsulation and retention strategies utilized, and the properties of the drugs chosen for encapsulation, all play an important role in determining the effectiveness of a particular liposomal drug. These properties should be carefully tailored to the specific drug, and to the application for which the therapeutic is being designed. Liposomal carriers are also amenable to additional modifications, including the conjugation of targeting ligands or environment-sensitive triggers for increasing the bioavailability of the drug specifically at the site of disease. This review describes the rationale for selecting optimal strategies of liposomal drug formulations with respect to drug encapsulation, retention, and release, and how these strategies can be applied to maximize therapeutic benefit in vivo.


📜 SIMILAR VOLUMES


In vivo monitoring of tissue pharmacokin
✍ Benjamin L. Viglianti; Sheela A. Abraham; Charles R. Michelich; Pavel S. Yarmole 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 885 KB

## Abstract The purpose of this study was to determine if MnSO~4~/doxorubicin (DOX) loaded liposomes could be used for in vivo monitoring of liposome concentration distribution and drug release using MRI. In vitro results show that __T__~1~ shortening correlates with MnSO~4~ concentration. Using a

Chemodosimetry of in vivo tumor liposoma
✍ Benjamin L. Viglianti; Ana M. Ponce; Charles R. Michelich; Daohai Yu; Sheela A. 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 783 KB

## Abstract Effective cancer chemotherapy depends on the delivery of therapeutic drugs to cancer cells at cytotoxic concentrations. However, physiologic barriers, such as variable vessel permeability, high interstitial fluid pressure, and heterogeneous perfusion, make it difficult to achieve that g

Trends and developments in liposome drug
✍ Tianshun Lian; Rodney J. Y. Ho 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB

Since the discovery of liposomes or lipid vesicles derived from self-forming enclosed lipid bilayers upon hydration, liposome drug delivery systems have played a signi®cant role in formulation of potent drugs to improve therapeutics. Currently, most of these liposome formulations are designed to red

In vivo EPR spectroscopic imaging for a
✍ Ken-ichiro Matsumoto; Tomoaki Yahiro; Ken-ichi Yamada; Hideo Utsumi 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 939 KB

## Abstract We used the membrane‐impermeable nitroxyl radical 4‐trimethylammonium‐2,2,6,6‐tetramethylpiperidine‐1‐oxyliodide (CAT‐1) as a model drug encapsulated in liposomes in order to separately map the 2D distribution of both liposomal‐encapsulated CAT‐1 and free CAT‐1. Phantoms were prepared w